Held M, Scheible G
Arzneimittelforschung. 1981;31(6):1036-8.
In healthy subjects plasma concentrations of 2-benzenesulfonylamino-4-(beta-methoxy-ethoxy)pyrimidine (glymidine) are considerably elevated during ingestion of 600 mg oxyphenbutazone additionally to 500 mg glymidine per day. In contrast phenylbutazone has only a slight and not significant effect on the glymidine plasma concentrations. In vitro equilibrium dialysis experiments show a decrease of serum protein binding of glymidine after the addition of phenylbutazone and oxyphenbutazone. The increase of the glymidine plasma concentrations together with the decrease of serum protein binding is predestined to lead to an increased pharmacodynamic effect of the drug.